GHET1

Summary

GHET1 (gastric carcinoma proliferation enhancing transcript 1, HGNC:49425) is a long non-coding RNA gene on chromosome 7q36.1.

This gene encodes an unspliced long non-coding RNA that has been suggested to promote the proliferation of gastric carcinoma cells and bladder cancer cells.

Source: NCBI Gene 102723099 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:49425
Approved symbol	GHET1
Name	gastric carcinoma proliferation enhancing transcript 1
Location	7q36.1
Locus type	RNA, long non-coding
Status	Approved
Aliases	lncRNA-GHET1, GHET-1
Ensembl gene	ENSG00000281189
Ensembl biotype	lncRNA
OMIM	619888
Entrez	102723099
RNAcentral	URS00007E3B8C — lncRNA, 1913 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 lncRNA

ENST00000627071

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000627071 — 1 exons

Exon	Start	End
ENSE00003773195	148987527	148989432

Expression profiles

Bgee: expression breadth ubiquitous, 128 present calls, max score 86.53.

Top tissues by expression

216 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	86.53	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.33	gold quality
endothelial cell	CL:0000115	75.52	gold quality
islet of Langerhans	UBERON:0000006	64.50	gold quality
ganglionic eminence	UBERON:0004023	62.83	gold quality
cortical plate	UBERON:0005343	61.24	gold quality
ventricular zone	UBERON:0003053	58.74	silver quality
prefrontal cortex	UBERON:0000451	56.12	gold quality
pancreas	UBERON:0001264	55.17	gold quality
rectum	UBERON:0001052	54.73	gold quality
Brodmann (1909) area 9	UBERON:0013540	51.47	gold quality
lymph node	UBERON:0000029	51.19	gold quality
frontal cortex	UBERON:0001870	51.12	gold quality
testis	UBERON:0000473	50.88	gold quality
neocortex	UBERON:0001950	50.88	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	50.35	gold quality
vermiform appendix	UBERON:0001154	49.93	gold quality
anterior cingulate cortex	UBERON:0009835	49.85	gold quality
cerebellar cortex	UBERON:0002129	49.69	silver quality
cerebellar hemisphere	UBERON:0002245	49.53	gold quality
right frontal lobe	UBERON:0002810	49.50	gold quality
gall bladder	UBERON:0002110	49.43	gold quality
cerebellum	UBERON:0002037	48.99	silver quality
cerebral cortex	UBERON:0000956	48.82	gold quality
right adrenal gland cortex	UBERON:0035827	48.73	gold quality
calcaneal tendon	UBERON:0003701	48.07	silver quality
smooth muscle tissue	UBERON:0001135	47.79	gold quality
esophagus mucosa	UBERON:0002469	47.64	gold quality
caecum	UBERON:0001153	47.34	gold quality
right hemisphere of cerebellum	UBERON:0014890	47.18	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.93

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 26)

• Data suggest GHET1 is prognostic factor for gastric carcinoma; GHET1 promotes c-Myc (proto-oncogene proteins c-Myc) mRNA stability/expression, binds IGF2BP1 (insulin-like growth factor 2 mRNA binding protein 1), and promotes gastric carcinoma growth. (PMID:24397586)
• GHET1 was up-regulated in bladder cancer and promoted the proliferation and invasion of bladder cancer cells. (PMID:25400817)
• the expression of GHET1 was significantly upregulated in CRC tissues compared with the matched adjacent normal tissues. We also showed that GHET1 promoted the proliferation and invasion of CRC cells. (PMID:27131316)
• GHET1 gene and protein expressions were significantly increased in gastric cancer tissues. (PMID:28577495)
• LncRNA GHET1 was intimately involved in the occurrence and development of HCC through regulating ATF1. (PMID:28772210)
• Our study indicates that GHET1 acts as an oncogene in esophageal squamous cell carcinoma (ESCC)and may represent a novel therapeutic target for the treatment of ESCC patients. (PMID:28983895)
• GHET1 could epigenetically repress transcription of Kruppel-like factor 2 in hepatocellular carcinoma cells by recruiting PRC2 into KLF2 promoter region and predicts poor prognosis. (PMID:29139562)
• GHET1 was relatively highly expressed in pancreatic cancer tissues and cells, and the highly expressed GHET1 was positively correlated with TNM staging. The inhibition of GHET1 expression inhibited the proliferation capacity of tumor cells, arrested cell cycle in G1/G0 phase and promoted apoptosis. (PMID:29228419)
• GHET1 were significantly upregulated in NSCLC tissues and cells. Furthermore, inhibition of GHET suppressed cell proliferation, invasion and EMT process. (PMID:29286919)
• LncRNA GHET1 might be a biomarker and molecular target of non-small cell lung cancer (NSCLC), providing a potential therapeutic target of NSCLC (PMID:29762836)
• Our results demonstrated that GHET1 was up-regulated in breast cancer tissues and cell lines, and promoted breast cancer cell proliferation, invasion and migration by affecting EMT. (PMID:29843220)
• the downregulation of GHET1 not only inhibits the migration and invasion of gastric cancer cells, but also inhibits their proliferation, at least in part by upregulating P21 expression and downregulating cyclin and CDK expression to inhibit the G0/G1 to S phase transition. (PMID:30066922)
• The GHET1 performs key functions in carcinogenesis and progression, suggesting that GHET1 is expected to be a prospective biomarker or therapeutic target for cancers. (PMID:30399371)
• GHET1 was up-regulated in osteosarcoma tissues and cell lines, inhibited cell apoptosis, promoted cell proliferation, invasion and migration by affecting EMT in vitro, and was correlated with the tumor growth and metastasis in vivo. GHET1 may be a potential therapeutic target of osteosarcoma treatment (PMID:30475755)
• lncRNA GHET1 has effects in development of pre-eclampsia. (PMID:30861585)
• GHET1 expression is significantly increased in cervical cancer.GHET1 role in the cervical cancer cell proliferation, migration, and invasion. (PMID:30948501)
• Findings indicate that non-coding RNA gastric carcinoma high expressed transcript 1 (GHET1) interacted with von Hippel-Lindau (VHL) and up-regulated hypoxia inducible factor 1 subunit alpha (HIF1alpha). (PMID:30988076)
• High expression of GHET1 was related with the low sensitivity to Gemcitabine of bladder cancer; GHET1 contributed to chemotherapeutic resistance to Gemcitabine through up-regulating ABCC1 expression. (PMID:31115606)
• Prognostic significance of LncRNA GHET1 expression in various cancers: a systematic review and meta-analysis. (PMID:31227613)
• LncRNA GHET1 promotes osteoblast proliferation and differentiation by inhibiting PTEN. (PMID:31355610)
• LncRNA GHET1 promotes cervical cancer progression through regulating AKT/mTOR and Wnt/beta-catenin signaling pathways. (PMID:31682716)
• Elevated lncRNA GHET1 levels in cancer tissues are significantly related to a greater risk of mortality, progression, and metastasis. Therefore, lncRNA GHET1 could be used as a novel clinical biomarker. [Meta-Analysis] (PMID:31885739)
• Knockdown of long non-coding RNA GHET1 suppresses cervical carcinoma in vitro and in vivo. (PMID:32176622)
• Long noncoding RNA GHET1 promotes osteosarcoma development and progression via Wnt/betacatenin signaling pathway. (PMID:32319657)
• Long noncoding RNA GHET1 promotes cell proliferation through oxidative stress in prostate cancer. (PMID:37029520)
• A review on the role of GHET1 in different cancers. (PMID:37244053)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.